FDAnews
www.fdanews.com/articles/82749-inhibitex-gives-trial-update-for-veronate

INHIBITEX GIVES TRIAL UPDATE FOR VERONATE

November 29, 2005

Inhibitex has announced updated trial information on its lead drug candidate, Veronate, which it is developing for the prevention of hospital-associated infections in very low-birth-weight infants.

In a Phase II trial of Veronate in premature infants weighing between 500 and 1,250 grams at birth, a higher infection rate was observed in the lower-birth-weight infants. Specifically, a 12 percent S. aureus infection rate was observed in infants that received placebo and weighed between 500 and 900 grams at birth, compared to a 7 percent S. aureus infection rate in the overall placebo cohort. Further, in infants weighing between 500 and 900 grams at birth, a 75 percent relative reduction in S. aureus infections was seen in those neonates that received 750 mg/kg of Veronate as compared to those that received placebo.